Vinodh R. Nannan Panday

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

S. Rodenhuis, J. Schellens, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study

J. Beijnen, J. Mulder, R. Hoetelmans, 1999, Cancer Chemotherapy and Pharmacology.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

J. Schellens, J. Beijnen, L. V. van Warmerdam, 1999, Journal of Cancer Research and Clinical Oncology.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

G. Giaccone, J. Schellens, J. Beijnen, 2000, Anti-cancer drugs.

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours

J. Schellens, H. Rosing, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.